Evidence map›Paper›PMID 35480407›Full record

ArticleThe Pan African medical journal2022

Correlation genotype-phenotype:

Hakima Missoum, Najlae Adadi, Mohammed Alami, Hamza Toufik, Abdelhakim Bouyahya, Fatima-Zahra Laarabi, Fatima Bachir, Abdellah El Maghraoui, Youssef Bakri

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hakima MissoumLaboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, and Genomic Center of Human Pathologies, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Najlae AdadiDepartment of Medical Genetics, National Institute of Health, Rabat, Morocco.
Mohammed AlamiLaboratory of Microbiology and Molecular Biology, Faculty of Science, Mohammed V University, Rabat, Morocco.
Hamza ToufikRheumatology Department, Faculty of Medicine and Pharmacy, Military Hospital, Mohammed V University, Rabat, Morocco.
Abdelhakim BouyahyaLaboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, and Genomic Center of Human Pathologies, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Fatima-Zahra LaarabiDepartment of Medical Genetics, National Institute of Health, Rabat, Morocco.
Fatima BachirLaboratory of Flow Cytometry, National Institute of Hygiene, Rabat, Morocco.
Abdellah El MaghraouiRheumatology Department, Faculty of Medicine and Pharmacy, Military Hospital, Mohammed V University, Rabat, Morocco.
Youssef BakriLaboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, and Genomic Center of Human Pathologies, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Mohammed V University · MAInstitut National d'Hygiène du Maroc · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting the joints. Arthritic disorders are associated with mutations of the Mediterranean fever (MEFV) gene. The aim of this study is to show whether MEFV mutations will be involved in the pathogenesis of RA, to explore the frequency of these mutations and to study the genotype-phenotype correlation between mutations in this gene and a cohort of Moroccan patients with rheumatoid arthritis (RA). Methods: the present study included 100 patients with RA and 200 control group (CG) who were unrelated individuals from the same ethnic. All patients were tested for auto-antibodies: cyclic citrullinated peptide (ACPA/anti-CCP Results: we detected 13 missense variants already MEFV gene mutation reported in the literature (S154T, G222A, G230L, L611H, L695A, M694V, I720M, A737L, P758S, L709A, T732A, G687A and P743L). Carrier rates of MEFV gene mutations were 24/100 (24%) for the RA group and 4/200 (4%) for CG. In the RA group, we observed that no man has presented with MEFV mutation. In the RA group, while gender, BMI, RF and ACPA were significantly higher in the mutation carrier group than those of the non-carrier group (p<0.01). The level of C-reactive protein and HAQ were slightly elevated in the carrier group but not significant. No other significant differences were observed between patients with MEFV mutations and those without MEFV mutations. Conclusion: the results of this study suggest that MEFV gene mutations appear to be an aggravating factor severity of RA and consequently, patients with RA might be screened for MEFV gene mutations in countries where FMF is frequent. We report also that our study is the first one in our country Morocco.

Indexed as

Arthritis, RheumatoidGenotypeHumansMutationPhenotypePyrinRheumatoid FactorMEFV protein, humanPyrinRheumatoid Factoranti-citrullinated peptide antibodiesautoimmune diseaseMEFV gene mutationsRheumatoid arthritisrheumatoid factor

Identifiers

PMID35480407
PMCPMC9011912
OpenAlexW4211198689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.